New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
20:25 EDTPFE, PFE, PFE, PFE, AMGN, AMGN, AMGN, AMGN, PBYI, PBYI, PBYI, PBYI, LLY, LLY, LLY, LLY, MDVN, MDVN, MDVN, MDVN, CLDX, CLDX, CLDX, CLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
News For PFE;AMGN;PBYI;LLY;MDVN;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 13, 2014
07:38 EDTPFEBloomberg Link to hold a conference
The Year Ahead: 2015 is being held in Washington, D.C. with a pre-conference dinner on November 13 followed by company presentations on November 14,
07:10 EDTCLDXSociety for NeuroOncology to hold a meeting
Subscribe for More Information
November 12, 2014
11:17 EDTPFE, CLDX, MDVNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:13 EDTPFEBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
November 11, 2014
16:14 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:05 EDTAMGNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTPFE, CLDX, MDVNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
10:44 EDTAMGNAmgen reaffirms 2015 adjusted EPS outlook $9.05-$9.40
Subscribe for More Information
November 10, 2014
16:32 EDTPBYIPuma Biotechnology reports Q3 EPS (84c), consensus ($1.21)
Subscribe for More Information
16:28 EDTCLDXOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
15:54 EDTAMGNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
November 7, 2014
07:19 EDTMDVNMedivation price target raised to $130 from $118 at Bernstein
Subscribe for More Information
06:41 EDTMDVNMedivation price target raised to $122 from $116 at Citigroup
Subscribe for More Information
November 6, 2014
16:49 EDTMDVNMedivation sees 2014 revenue at high end or above guidance
Medivation sees 2014 U.S. net sales of XTANDI, as reported by Astellas, at the high end or just above the previously-guided range between $600M-$640M. Total collaboration revenue is expected to be at the high end or just above the previously-guided range between $615M-$640M, which includes collaboration revenue related to U.S. net sales of XTANDI that is expected to be at the high end or just above the previously-guided range between $300M-$320M, and collaboration revenue related to upfront and milestone payments of approximately $279M. The consensus revenue estimate is $647.33M.
16:47 EDTMDVNMedivation reports Q3 EPS 96c, consensus 84c
Subscribe for More Information
16:26 EDTAMGNAmgen announces more than 50 abstracts accepted for presentation
Subscribe for More Information
15:27 EDTMDVNNotable companies reporting after market close
Subscribe for More Information
09:36 EDTPFEGlycoMimetics announces presentation of GMI-1271, rivipansel
Subscribe for More Information
06:35 EDTPFEAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use